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Abstract. Several potential urinary biomarkers exhibiting 
an association with upper gastrointestinal tumour growth 
have been previously identified, of which S100A6, S100A9, 
rabenosyn-5 and programmed cell death 6-interacting 
protein (PDCD6IP) were further validated and found to be 
upregulated in malignant tumours. The cancer cohort from 
our previous study was subclassified to assess whether distinct 
molecular markers can be identified for each individual cancer 
type using a similar approach. Urine samples from patients 
with cancers of the stomach, oesophagus, oesophagogastric 
junction or pancreas were analysed by surface‑enhanced laser 
desorption/ionization‑time‑of‑flight mass spectrometry using 
both CM10 and IMAC30 (Cu2+-complexed) chip types and 
LC‑MS/MS‑based mass spectrometry after chromatographic 
enrichment. This was followed by protein identification, 
pattern matching and validation by western blotting. We found 
8 m/z peaks with statistical significance for the four cancer 
types investigated, of which m/z 2447 and 2577 were identified 
by pattern matching as fragments of cathepsin‑B (CTSB) and 
cystatin‑B (CSTB); both molecules are indicative of pancreatic 
cancer. Additionally, we observed a potential association of 
upregulated α-1-antichymotrypsin with pancreatic and gastric 
cancers, of PDCD6IP, vitelline membrane outer layer protein 
1 homolog (VMO1) and triosephosphate isomerase (TPI1) 
with oesophagogastric junctional cancers, and of complement 
C4-A, prostatic acid phosphatase, azurocidin and histone-H1 
with oesophageal cancer. Furthermore, the potential 
pancreatic cancer biomarkers CSTB and CTSB were validated 
independently by western blotting. Therefore, the present study 
identified two new potential urinary biomarkers that appear 
to be associated with pancreatic cancer. This may provide a 
simple, non‑invasive screening test for use in the clinical setting.
Introduction
A significant number of cancer‑related deaths worldwide are 
associated with malignant tumours of the upper gastrointestinal 
(GI) tract, such as the stomach, oesophagus, oesophagogastric 
junction (OGJ) (1) and pancreas. The Global Burden of Disease 
study undertaken in 2015 identified these types of cancer to 
have a very poor prognosis, with gastric and oesophageal 
cancers contributing to 10.3 and 5.4%, respectively, of all cancer 
deaths globally, with both exhibiting a male preponderance (2). 
Pancreatic cancer is associated with a dismal 5-year survival rate 
of 3% and its incidence appears to be increasing annually (3,4). 
This has led to the development of various therapeutic strategies 
to prolong survival, which have had limited success, including 
improved surgical techniques, anti-angiogenesis therapies and 
adjuvant/neoadjuvant chemoradiotherapy (5,6). Pancreatic 
cancer cases in particular are usually diagnosed at an advanced 
stage and, therefore, the possibility of a non‑invasive interven-
tion to halt tumour progression is greatly reduced. Therefore, it 
is crucial to devise methodologies to not only pharmacologically 
treat, but also to diagnose this type of cancer at an early stage.
The most successful and widely used cancer assays to date 
are based on the detection and quantification of glycans in 
the serum using antibodies against CA19.9 (7) or CA125 (8), 
a pan-cancer marker that targets carbohydrate-associated 
epitopes of immunoglobulin heavy chains (9). CA19.9, with a 
reported sensitivity of 90‑100% and specificity of 70‑98% for 
pancreatic cancer detection (10), is the best biomarker assay 
currently in clinical use. However, the positive predictive value 
of CA19.9 for detecting pancreatic cancer is only 0.9% in the 
asymptomatic population due to a dependency of blood‑group 
markers where CA19.9 can be used (11). It is also associated with 
biliary obstruction (12) and has been proven unable to distin-
guish pancreatic cancer from matched controls in larger studies, 
highlighting its poor clinical utility as a tumour marker (13).
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Other potential cancer protein biomarkers have been identi-
fied by antibody arrays, such as H2B histone using the IPO‑38 
antibody to define gastric cancer (14), M2 pyruvate kinase 
in faeces as a GI cancer marker (15) and tumour‑associated 
trypsin inhibitor as a marker of liver metastasis and colorectal 
cancer (16), and by mass spectrometry, such as S100A9 for 
upper GI cancer (17), as well as S100A6 for a wide array of 
tissue cancers, including thyroid (18), gastric (19), ovarian (20), 
hepatocellular (21), bowel (22), breast (23) and upper GI (17) 
cancers.
Numerous potential biomarkers were also identified by 
gene array screens of diseased tissue (24‑27) and by microRNA 
array screens of circulating biofluids (28), in the most frequent 
cancers affecting the GI tract (29,30). The latter is considered 
as a promising source of clinically relevant biomarkers, when 
compared with tissue gene array screens, since the use of 
biopsies as a predictive diagnostic tool remains unrealistic 
for use in the clinical setting. Additionally, prediction of 
several cancer types based on serum metabolic profiles is also 
feasible (31). Concomitantly, collaborative efforts have been 
made to promote the detection of plasma‑derived metabolite 
markers for pancreatic cancer diagnosis (32,33).
There is a clear need to simplify the medium to be screened 
due to genetic variations and population heterogeneity in order 
to define reliable disease markers. A substantially less complex 
system, such as the urine, which contains ~5,000 proteins (34), 
would be a preferred medium to screen for protein or peptide 
biomarkers. This has a number of advantages, including 
non‑invasive sampling for patients, ease of sampling, and 
unrestricted availability under normal conditions (35). Urine 
itself is also relatively stable in terms of protein and peptide 
composition and fragmentation state compared with other 
body fluids, such as the serum, where proteolytic degradation 
by endogenous proteases has been shown to occur during or 
after sample collection (36).
In the present  study,  sur face‑enhanced laser 
desorption/ionization‑time‑of‑flight mass spectrometry 
(SELDI-TOF-MS) was used to screen human urine samples 
from patients with upper GI tumours to establish biomarker 
patterns using the CM10 and IMAC30 chip types, as well 
as independent LC-MS/MS mass spectrometry screening 
and a combined bioinformatics data analysis, in order to 
present a potentially useful approach to diagnosing upper GI 
tissue type‑specific cancers in humans using novel potential 
biomarkers.
Materials and methods
Materials. All buffers, gels and SELDI chips were purchased 
from Bio‑Rad Laboratories Ltd. (Hemel Hempstead, UK), and 
all other chemicals were obtained from Sigma‑Aldrich; Merck 
KGaA (Gillingham, UK), unless stated otherwise in the text.
Sample collection. Urine samples were obtained from 
83 patients with upper GI cancers undergoing potentially cura-
tive resection. The participant demographics are summarised 
in Table I and provided in detail in Table SI. The participants' 
age ranged between 43 and 83 years. Fasting urine samples 
were obtained at induction of anaesthesia. One‑third of the 
patients had pancreatic tumours, one-third had oesophageal 
cancer, approximately one‑sixth had malignancies of the OGJ 
and one‑sixth suffered from gastric cancer. All procedures 
were approved by the local research ethics committee and 
written informed consent was obtained from the patients. The 
study conformed to the standards set by the Declaration of 
Helsinki. All urine samples were stored at ‑40˚C. Long‑term 
storage of samples (>1 month) was at ‑80˚C.
SELDI‑TOF‑MS. SELDI chips (CM10 and IMAC30) were 
prepared for sample application according to the manufac-
turer's recommendations. Briefly, IMAC30 chips were loaded 
with 0.1 M CuSO4, washed with water, neutralised with 0.1 M 
NaHAc (pH 4.0) and again washed with water, followed by 
two washes with 0.1 M NaHPO4 and 0.5 M NaCl; CM10 chips 
were washed twice with 0.1 M NaHPO4 (pH 4.0). All chips 
were processed in a bioprocessor assembly by incubating 
0.1 ml urine and 0.1 ml binding buffer [IMAC30: 0.1 M 
NaHPO4, 0.5 M NaCl; CM10: 0.1 M NaHPO4 (pH4.0)] for 
1 h at room temperature with vigorous shaking, followed by 
three washes with 0.2 ml binding buffer for 5 min each at 
room temperature with vigorous shaking and two washes with 
0.2 ml water at room temperature with vigorous shaking. All 
chips were removed from the bioprocessor assembly, air‑dried 
and 1 µl energy‑absorbing matrix [a saturated solution of 
sinapinic acid in 50% acetonitrile (ACN) and 0.5% trifluoro-
acetic acid] was added twice. Air-dried chips were analysed 
in a PCS4000 SELDI-TOF instrument (Bio-Rad Laboratories, 
Ltd.) by measuring the 1,000-25,000 Da range with a low laser 
setting of 2.5 µJ, and spectra were exported as ‘.xml’ files. 
The SELDI instrument was calibrated using the ProteinChip 
All-In-one peptide standard (Bio-Rad Laboratories, Ltd.). The 
source voltage was 25,000 V and the detector voltage was 
2,946 V. Quality control and consistency were ensured by 
using one random pool of urine samples on one spot per chip 
each. Spectra of the full analysis were recorded in two large 
batches to minimize instrument variability and drift. Spectral 
alignments of all quality controls ensured consistency of all 
spectra.
SELDI‑TOF‑MS data processing. ProteinChip Data Manager 
Software version 4.1 with integrated Biomarker Wizard 
cluster analysis (Bio‑Rad Laboratories, Ltd.) was used for 
analysis. SELDI‑TOF‑MS traces were split into the four 
cancer type groups. The baseline was subtracted from 
individual m/z traces and the profiles were normalised using 
total ion current, followed by identification of peak clusters 
using the cluster analysis tool. Peaks were selected in the 
first pass with a signal‑to‑noise (S/N) ratio of >5 and a valley 
depth of at least 3, and in the second pass with a S/N of 2 
and a valley depth of 2. The cluster mass window was set 
to 0.2% of the mass. Clustered peaks were only included if 
they occurred in at least 10% of all spectra. The resulting 
P‑values, mean and median m/z values, and the intensities of 
the clustered peaks were exported and saved as ‘.csv’ files. 
A two-sample t-test was used to compare mean normalized 
intensities between the groups. The P-value was set at 0.05 to 
indicate statistically significant differences. Clustered peak 
lists were analysed with the Biomarker Pattern Software 
(Bio-Rad Laboratories, Ltd.) and m/z vs. intensity matrices 
were analysed using decision tree analysis, selecting the 
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standard error rule of minimum‑cost tree regardless of size, 
and using the Gini method. V‑fold testing was set to 1,000. All 
samples from one cancer type were used to build exploratory 
networks by using all other cancer samples as ‘negative’ 
controls. Tree model building was performed using a selected 
m/z peak as the only deciding factor to obtain sensitivity and 
specificity values. Sensitivity was defined as the probability of 
predicting specific cancer cases, and specificity was defined 
as the probability of predicting other cancers.
Peak isolation and identification by LC‑MS/MS and Mascot 
searching. Peaks observed in the CM10 and IMAC30 
chip types (Table SIII) that exhibited marked expression 
differences between tissue‑specific cancer samples, and 
statistical significance in the cluster analyses with P<0.05, 
were further investigated. Urine (0.5 ml) from positive or 
negative samples in relation to specific peaks was added 
to 30 µl CM10 or IMAC30 (Cu2+-complexed) spin column 
resin (Bio-Rad Laboratories, Ltd.) and 0.75 ml binding 
buffer [0.1 M NaHPO4 (pH 4.0) for CM10 resins, and 0.1 M 
NaHPO4 (pH 7.0) including 0.5 M NaCl for IMAC30 resins] 
and incubated for 1 h at room temperature under constant 
agitation. Unbound material was removed and the resin was 
washed four times with 0.3 ml binding buffer. Bound material 
was separated by electrophoresis on a 16.5% Tris-Tricine gel 
(Bio-Rad Laboratories, Ltd.), and gel bands in the region 
of 2‑10 kDa were excised following Coomassie staining 
(BioSafe Coomassie; Bio‑Rad Laboratories, Ltd.). Positive 
and negative samples were both selected on the presence 
and absence of a specific m/z peak to be identified based 
on SELDI‑TOF‑MS analysis. Proteins and peptides from 
gel bands were digested in situ with trypsin, the resulting 
peptides eluted with ACN, and analysed by LC-MS/MS 
as described previously (17). Data-dependent acquisition 
was controlled by Xcalibur software and fragmentation 
spectra were then processed by Xcalibur and BioWorks 
software (Thermo Fisher Scientific, Inc., Loughborough, 
UK) and submitted to the Mascot search engine (Matrix 
Science, London, UK) using UniProt/SwissProt (release 
July 2010, Homo sapiens, 18055 sequences) as the reference 
database. The Mascot search parameters were as follows: 
Enzyme specificity, trypsin; maximum missed cleavage, 
1; fixed modifications, cysteine carbamidomethylation; 
variable modification, methionine oxidation; precursor mass 
tolerance, ±3 Da; and fragment ion mass tolerance, ±0.4 Da. 
Only Mascot hits with a false discovery rate of <0.05 were 
taken into consideration.
Mascot‑SELDI matrix matching. Observed proteins with 
at least two peptide matches from the LC‑MS/MS analysis 
were then further analysed by pattern matching based on 
SELDI‑TOF‑MS measured expression levels of peaks of 
interest (expected abundance in selected samples). This was 
performed using software written in‑house, which compares 
observed protein expression patterns in a pre‑defined set of 
samples (LC‑MS/MS results) against a matrix of peak patterns 
(SELDI-TOF clustered peak intensities, where estimated peaks 
are set to null) in the same set of samples. The scoring is based 
on sensitivity (percent observed over expected) and specificity 
(percent not observed over not expected), and the results are 
presented in descending order of cumulative scores.
Western blotting and validation of Mascot search results. 
Cross‑validation of identified peaks was performed by western 
blotting of raw urine samples for anti‑cathepsin B (CTSB) and 
anti-cystatin B (CSTB) blots (20 µl per sample) using standard 
protocols (37). The antibodies used were rabbit anti-human 
CTSB (G-60; 1:1,000; cat. no. 3373; Cell Signaling Technology, 
Danvers, MA, USA), rabbit anti-human serum albumin (1:1,000; 
cat. no. A3293; Sigma-Aldrich; Merck KGaA), mouse anti-human 
CSTB (1:400; cat. no. sc-101510; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), and the peroxidase-coupled secondary 
antibodies were from Upstate (Lake Placid, NY, USA), used 
at a dilution of 1:5,000. Detection of signals was performed 
by chemiluminescence using ECL western blotting reagents 
(Thermo Fisher Scientific, Inc., Cramlington, UK).
Results
Urinary screening via SELDI‑TOF‑MS analysis. Urine 
samples from 83 patients diagnosed with various types of upper 
GI cancer were analysed in the course of this study (Table I). 
A full demographic with additional clinical data is provided 
in Table SI. The mean age of the participants was 65 years, 
34% of the cohort suffered from pancreatic cancer, 33% from 
oesophageal cancer, 18% from gastric tumours and 15% from 
cancer of the OGJ. SELDI‑TOF‑MS analysis was selected to 
screen the samples mentioned above based on our previous 
study, where we described global specific markers for upper 
GI cancer (20). We found that both the metal chelator resin 
IMAC30 (Cu2+-chelated) and the weak cation exchanger CM10 
yielded the best and most reproducible results. All samples 
were measured by SELDI‑TOF‑MS to obtain a peak pattern of 
identified molecular constituents, allowing us to stratify tissue 
type‑specific cancers. We selected to compare only samples 
Table I. Demographics of the cohort used in this study (n=83). 
 
Cancer typea Oesophagus Pancreas OGJ Gastric Total
 
No. of patients 27 28 13 15 83
Mean ageb (years) 66.5 (10.8) 63.5 (9.1) 61.5 (8.1) 70 (7) 65.3 (9.5)
Male 22 16 12 9 59
Female 5 12 1 6 24
 
aBased on the histological assessment of each tumour type. bMean age of the participants according to the various groupings (standard deviation). Sex 
breakdown (male/female) and the total sample numbers (total) of the groups is included as number of participants. OGJ, oesophagogastric junction.
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from cancer patients against each other to circumvent the issue 
of accidentally tracking lead markers that may be associated 
with additional underlying conditions, such as inflammatory 
responses, which are commonly observed in cancer patients.
SELDI analysis of the CM10 chip type‑based screen of 
the 83 cancer urine samples resulted in 9,379 peaks, and the 
IMAC30 chip analysis provided a cumulative peak list of 
3,346 features (Table SII). Clustering of observed peaks using 
the thresholds described in Materials and methods resulted 
in 328 cluster peaks for the CM10 chips, and the IMAC30 
chip type gave yield to 92 common peak clusters above the 
set thresholds (Table SIII). Both analyses were performed 
by omitting estimated peaks in order to restrict and raise 
the specificity of potential marker peaks and, therefore, only 
included well‑defined and separated individual peaks from all 
spectra. Statistical analysis revealed that 8 peak clusters are 
potentially associated with the various cancer types, namely 
m/z 2444 and 2557 for pancreatic cancer in the IMAC30 set, 
and m/z 2447 and 9618 in the CM10 chip‑based set for the same 
cancer type, m/z 5511 and 4908 for OGJ cancer and m/z 4639 
for gastric cancer in the IMAC30 chips, and m/z 4141 for 
oesophageal cancer in the CM10 chip set (Fig. 1; Table II). All 
potential markers have P<0.05 and exhibit upregulation in the 
associated disease. It is noteworthy to mention that any given 
peak cluster can comprise more than one molecular entities. 
Therefore, it is possible that both the 2444 and 2447 m/z peaks 
share an overlap in their molecular constituents; however, 
they include other peptides or proteins which are unique 
in this specific peak cluster based on the sensitivity and 
specificity distribution. The frequency distribution analysis 
of those 8 peaks shows that the m/z 9618 cluster from the 
CM10 chip screen displays the best stratifier for pancreatic 
cancer (Fig. 1D), with a sensitivity of 61% and a specificity of 
82% in upper GI cancer cases. Comparison of all 8 peaks in 
non-cancer control cases measured in our previous study (17) 
also demonstrated that the m/z 9618 peak cluster exhibits 
the same frequency distribution in both non‑cancer and 
non‑pancreatic cancer cases of ~30%, whereas this frequency 
is doubled in pancreatic cancer for this peak cluster. The best 
predictor, based on a low frequency in non‑cancer cases, was 
the m/z 2577 cluster in pancreatic cancer (Fig. 1B), with a 
79% frequency in this cancer type, a 62% frequency in other 
cancers, and a 10% occurrence in non-cancer patient urine, 
with a sensitivity of 86% and a specificity of 44%. The elevated 
amount of the observed m/z 4141 peak cluster associated with 
oesophageal cancer (Fig. 1H) demonstrates the best specificity 
of 100%, but exhibits a relatively poor sensitivity of only 19% 
due to the relatively low frequency of one in four samples where 
this peak can be measured. Low frequency values were also 
observed for the OGJ cancer‑associated elevated peak cluster 
at m/z 4908 (Fig. 1F), with good sensitivity and specificity 
values of 92% and 66%, respectively. A more pronounced 
potential OGJ marker in terms of quantitative changes was 
measured at m/z 5511 (Fig. 1E) with a high specificity (94%), 
but a relatively low sensitivity (38%).
We then endeavoured to identify the molecular identity 
of the m/z 2447 peak, since it showed the highest sensitivity 
of 100% in the detection of pancreatic cancer. This was 
performed by selecting 8 samples, of which 4 either contained 
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according to the SELDI-TOF scans. The samples were indi-
vidually batch-absorbed on CM resin; bands in the 2-4 kDa 
range were excised after peptide gel electrophoresis and 
processed as described previously (17). The molecular cluster 
of interest was shown to consist of fragments from CTSB, 
α-1-antichymotrypsin precursor and immunoglobulin γ and κ 
chains (Table III). The same result was obtained using an 
independent approach, as described below.
We then analysed the molecular constituents of human 
cancer patient urine in the 2-10 kDa molecular weight range 
using chromatographic protein and peptide enrichment on 
CM10 and IMAC30 resins, followed by gel separation, trypsin 
digestion and LC‑MS/MS fragmentation, as before. Samples 
were selected based on the SELDI-TOF analysis results to 
either contain the 8 m/z peaks of interest (50% of samples per 
subset) or not in subsets of groups of 16 samples each. This 
resulted in the analysis of 145 urine samples, including repeats, 
from 62 upper GI cancer patients, of which 42 unique patient 
urines were enriched on CM10, and 40 unique patient samples 
on IMAC30 chromatography resins. 950 non-redundant 
proteins were identified in the CM10 resin‑based approach by 
Mascot searching, and 600 unique proteins could be observed 
in the IMAC30-based enrichment, totalling 1,228 unique and 
non-redundant proteins in the combined datasets (Table SIV). 
Protein expression pattern matching (i.e., molecules identified 
by LC-MS/MS and Mascot searching, and matching to peak 
expression patterns observed by SELDI‑MS) was performed 
by using an automated computer program written in-house 
based on the filtered Mascot dataset, where each individual 
identification was based on Mascot scores >16 and consisting 
of at least 2 peptides each. All proteins were identified in 
at least three independent samples. Table III lists all found 
by this approach, including a list of publications describing 
the relevance of these molecules in tumour growth. A fully 
detailed list of these molecules, including peptide sequences, 
is supplied in Table SV.
The m/z 2444 peak observed in pancreatic cancer using 
the IMAC30 chromatography resin, as well as the pancreatic 
cancer-associated m/z 2447 peak in the CM10 dataset, matched 
the expression pattern of α-1-antichymotrypsin (SERPINA3 or 
AACT). The same molecule, although a different proteolytic 
fragment of m/z 4639, could also be a potential biomarker for 
gastric cancer. A fragment of CSTB matched the observed 
pancreatic marker of m/z 2577 in the IMAC30 resin 
type-derived dataset, and other potential pancreatic markers 
of m/z 2477 and 9618 matched the presence of peptides from 
immunoglobulins. The m/z 2477 cluster distribution pattern 
also coincides with the measured expression pattern of CTSB.
Potential biomarkers for OGJ tumours include programmed 
cell death 6-interacting protein (PDCD6IP), matching the 
observed pattern of m/z 5511 in the IMAC30 resin dataset, 
vitelline membrane outer layer protein 1 homolog (VMO1) 
and triosephosphate isomerase (TPI1), which matched the 
m/z 4908 peak pattern in SELDI-TOF-MS measurements. 
The m/z 4141 clustered peak in the CM10 enriched dataset, 
which may be indicative of oesophageal cancer, matched the 
LC‑MS/MS observed expression pattern of several molecules, 
namely complement C4-A (C4A), prostatic acid phosphatase 
(ACPP), azurocidin (AZU1) and histone H1.2, H1.3 or H1.4.
Both CTSB and CSTB were also cross-validated by 
western blot analysis (Fig. 2), and both molecules exhibited 
a very good correlation to the expected cluster-peak pattern 
observed by SELDI analysis, thereby validating both the 
predictor model and the Mascot identification, as well as the 
SELDI peak clustering of these molecules, and may represent 
viable prognostic biomarkers for pancreatic cancer.
Figure 1. Expression profiling of potential biomarkers. The expression profiles of six potential markers specific for the four cancer types are displayed as 
whisker plots (median, lower and upper quartile and upper and lower extreme values). The x‑axis contains the categorical variable representing four cancer 
types [oesophageal (red), pancreas (green), OGJ (blue) and gastric (pink)], while the y‑axis shows the normalised m/z intensity (arbitrary units). [(A) (m/z 2444), 
(B) (m/z 2577), (E) (m/z 5511), (G) (m/z 4639)] are derived from the IMAC30 chip type, and [(C) (m/z 2447), (D) (m/z 9618), (F) (m/z 4908), (H) (m/z 4141)] 
from the CM10 chip type (see Table II for m/z and fold‑change descriptions for panels A‑H). (A‑D) Potential pancreatic tumour markers; (E and F) OGJ 
marker; (G) gastric cancer marker; (H) oesophageal cancer marker. OGJ, oesophagogastric junction.
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Development of a cancer profiling database. Over the last decade, 
the emergence of high‑throughput screening platforms opened 
the possibility to mechanistically characterize at the molecular 
level disease phenotypes, disease subtypes, assess disease 
progression and monitor response to therapy. However, despite 
a crescendo in the availability of these large‑scale multi‑omics 
data for numerous conditions, no apparent or adequate effort has 
been made to curate and integrate those data resources.
Therefore, large‑scale multi‑omics data handling 
differential expression of several molecular entities, for 
example, microRNA, gene, protein and metabolite across 
multiple tissues and biological fluids in several cancer types 
(with special emphasis on GI neoplasms) were collected from 
the literature and general scope databases, and subjected to 
extensive manual curation and annotation. This effort yielded 
a cancer profiling database: the Multi‑Omics Cancer database 
MoCadb (www.padb.org/mocadb), a database module of the 
Pan-Omics Analysis Database (PADB) (www.PADB.org) 
which ensures a long‑term lifecycle of the created repository, 
along with providing the appropriate framework that encloses 
curated resources, in order to assist in the development of 
integrative ‑omics disease models, straightforward translation 
of findings from experimental animal models using established 
ortholog maps, creation of cellular regulatory networks based 
on the association of miRNAs and transcription factors to 
targets, protein-protein and gene-gene interactions, enzymatic 
reactions, delineation of pathways and drug interactions.
MoCadb aims to incorporate existing molecular informa-
tion and clinical metadata, ultimately holding the potential to 
unravel and allow an in‑depth understanding of the regulation 
of key molecules modulating pathophysiology and progression 
in several cancer types.
Discussion
The identification of potential novel biomarkers for ailments 
such as pancreatic cancer is of utmost importance, particularly 
in light of the shortcomings of the markers currently used in the 
clinical setting for diagnosis and disease progression monitoring. 
As an example, in a retrospective study, cohort screening using 
a bead‑based antibody array of a multi‑parametric signature 
of three serum biomarkers, namely CA19.9, intercellular adhe-
sion molecules 1 and osteoprotegerin, were able to distinguish 
patients with pancreatic ductal adenocarcinoma (PDAC) from 
healthy subjects, with a sensitivity/specificity of 88/90% and an 
area under the curve (AUC) of 0.93 (38). However, in a follow‑up 
study using a larger prospective cohort, the latter biomarker 
panel and the respective AUCs associated with the biomarker 
model were not statistically different, thereby failing to distin-
guish PDAC cases from matched controls (39). This highlights 
the current issues and challenges associated with biomarker 
research in pre‑diagnostic risk assessment of pancreatic cancer.
We selected an MS‑based proteomic screening of urine 
from upper GI cancer patients for prospective biomarkers 
for the four most prominent cancer types associated with 
the upper GI to establish a proteomic fingerprint pattern, as 
well as defined molecular markers, which can potentially be 
used in clinical diagnostics. In the clinical setting, urine is an 
optimal sample source, as it is easy to obtain, the collection 
is non‑invasive, and is relatively stable in terms of sample 
Figure 2. Validation of identified proteins by western blotting. Urine samples were separated by 20% SDS‑PAGE and analysed by western blotting using 
antibodies specific against CSTB, CTSB and albumin. Panels (A) and (C) (left) show the western blotting results of combined urine samples in the 1‑100‑kDa 
range. The samples were tested initially for the presence of fragments of CSTB and CTSB in the region of the measured m/z (open triangles), as well as 
full‑length molecules (filled triangles) or other breakdown products. Reliable signals in the 35‑kDa range for CSTB and 25‑kDa for CTSB were then further 
analysed. Validation and confirmation of LC‑MS/MS and Mascot results are shown in the strip‑blots in panels (A) and (C), which show the results of (A) 8 or 
(C) 7 urine samples that were used in LC‑MS/MS and subsequent Mascot searches, together with the cluster peak intensity matrices derived from the SELDI 
analysis (underneath the individual blots). Panels (B) and (D) depict the analysis of four random cancer and four control samples. The samples were selected 
based on the IMAC30 SELDI analysis for the presence of a peak cluster at m/z 2577 for CSTB, and on the CM10 SELDI peak pattern at m/z 2447 for CTSB 
(cancer samples) or the absence of these m/z peaks (healthy controls). ‘e’ corresponds to an estimated value (in brackets), where no peak at the m/z point could 
be detected above the S/N ratio. Qualitative loading control was performed by probing against the common urinary molecule serum albumin. Molecular weight 
indicators are depicted on the left, and the target proteins on the right of the blots. The cancer locus is the histologically assessed cancer site of duodenum (D), 
pancreas (P), oesophagogstric junction (OGJ), oesophagus (O), or non‑cancerous control (C). CTSB, cathepsin‑B; CSTB, cystatin‑B; SELDI, surface‑enhanced 
laser desorption/ionization; MS, mass spectrometry; S/N, signal-to-noise ratio.
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integrity. A substantial number of previous studies have 
found the SELDI‑TOF‑MS technique ideally suited for urine 
analysis, with a combination of high throughput, speed and 
relatively low cost (40‑42). However, a main drawback of 
this technique is the comparatively medium resolution of 
the spectra obtained, but this is adequate to resolve peaks in 
the 1‑25‑kDa range from spectra with <500 peaks. We have 
previously demonstrated that both IMAC30 and CM10 are 
useful chip types for the analysis of human urine (17), and 
we were able to generate a decision‑tree model for upper GI 
cancer with an overall sensitivity of 98% and a specificity 
of 87%. In the present study, we identified 8 peak clusters by 
SELDI‑TOF‑MS for the four cancer types studied and, using 
expression pattern matching, we were able to assign several 
proteins identified in the urine to our proposed biomarkers.
An elevated amount of SERPINA3 may be associated 
with both gastric and pancreatic cancer, and has also been 
reported as a potential urinary biomarker in non-small-cell 
lung cancer (43). SERPINA3 is a protease inhibitor that can 
modulate cathepsin G (44), and its glycosylated form is directly 
associated with colorectal cancer (45). This protein was already 
known to be associated with pancreatic cancer and could be 
detected in higher levels in the plasma (46,47). Furthermore, 
this marker was specifically negatively correlated with survival 
in patients with advanced pancreatic cancer (48). However, it 
is also worth noting that several different fragments from the 
same molecule were observed in our SELDI-TOF experiments, 
namely m/z 2444, 2447 and 4639, of which the latter is specific 
for gastric cancer. Additionally, we also identified the same 
molecule in our upper GI cancer screen (17) as m/z 8803. It 
is possible that a specific proteolytic fragment of SERPINA3 
is associated with and generated in a specific type of cancer, 
where the m/z 8803 fragment may be generic for upper GI 
cancer and the small fragments specific to pancreatic cancer. 
This is further substantiated by our observation that the 
protease CTSB is also a potential biomarker for pancreatic 
cancer. Additionally, CTSB was validated as a potential 
urinary biomarker in pancreatic carcinoma by western 
blotting. Furthermore, CTSB was reported to be a prognostic 
marker in pancreatic adenocarcinoma (49), which confirms our 
findings for this molecule and its potential as a lead marker in 
pancreatic cancer diagnostics. Another promising candidate as 
a pancreatic cancer biomarker was identified and verified as 
CSTB. The cysteine protease inhibitor CSTB was described 
as a protein that is able to stimulate cancer cell growth in vitro 
and in vivo (50). Other potential pancreatic cancer markers 
identified in this study comprise fragments of immunoglobulins. 
The occurrence of specific fragments of antibodies may be 
associated with the increased amounts of CTSB, or may be due 
to a host response to pancreatic tumour growth. Antibodies are 
also well-described and used in the clinical setting to assess 
various cancer types (e.g., CA19-9 in pancreatic cancer) (9,10).
Stratification of OGJ cancer cases by SELDI‑TOF‑MS 
revealed two potential m/z peak clusters, m/z 4908 and 5511. 
The latter peak cluster was identified to be a fragment of 
PDCD6IP (also referred to as AIP1 or ALIX), which has been 
described to participate in programmed cell death, and it was 
reported that its overexpression can block apoptosis (51). The 
m/z 4908 peak cluster consists of fragments from VMO1 and 
TPI. No role of VMO1 has been implicated in cancer, and 
this may be a novel target for OGJ cancer, whereas TPI was 
described in the literature to be upregulated in oesophageal 
cancer (52), as well as in hepatocellular carcinoma (53).
The oesophageal cancer marker of m/z 4141 appears to 
contain several molecular constituents, namely C4A, ACPP, 
AZU1 and fragments from Histone H1. C4A is an important 
component in the activation of the classical pathway of the 
complement system and proteolytic breakdown products of 
C4-A have been suggested as biomarkers in breast cancer (54), 
although a specific proteolytic product, C4a anaphylatoxin, is 
a mediator of local inflammatory processes (55). This protein 
is therefore potentially unsuitable as a diagnostic marker in 
oesophageal cancer. ACPP, a non‑specific tyrosine phosphatase, 
is well-described to be associated with prostate cancer (56), and 
is used clinically as a diagnostic marker. AZU1, an antibacterial 
and monocyte‑ and fibroblast‑specific chemotactic glycoprotein, 
which acts in conjunction with cathepsin G in host‑defense 
mechanisms (57), was hypothesized to be a potential pancreatic 
cancer biomarker in the pancreatic juice (58). Histones H1 have 
been reported to be involved in the survival of breast cancer 
cells (59), and H1.2 specifically was identified as an apoptogenic 
factor (60).
In conclusion, the approach of using SELDI‑MS to iden-
tify potential lead candidates as biomarkers associated with 
specific upper GI cancers is a useful tool that enabled us to 
identify potential global upper GI cancer markers, as well 
as potentially specific markers for individual cancer types, 
such as gastric, pancreatic, OGJ and oesophageal cancer. 
CSTB and CTSB, in particular, appear to be promising lead 
candidates, since these molecules are not commonly found 
in the urine, and have already been associated with pancre-
atic cancer in situ in the literature (61-63). Other potential 
lead markers may require further validation, such as western 
blotting and, ultimately, exact determination of the sensi-
tivity/specificity values of our novel proposed markers 
associated with specific disease states and their usefulness 
in a more general setting. Further studies, including an 
extended cohort, will help determine the validity of our find-
ings, and specific assays monitoring the expression levels of 
our proposed biomarkers will help to translate our findings 
into the clinical setting. One of the main hurdles to over-
come is a methodological/technical dependency, such as the 
use of the SELDI technology, which is not straightforward 
to translate into a clinical environment. A more appropriate 
approach would rely on techniques that are commonly in use, 
such as specific protein detection methods. Additional inves-
tigations are needed to explain the biological involvement of 
the proposed biomarkers in tissue type‑specific cancers and 
their presence in the urine. To aid in this task, and to add 
a higher level of contextualisation of individual markers or 
a panel of biomolecules, information held in our MoCadb 
database, and in other databases within the PADB initia-
tive, can guide the biomarker identification process. Future 
expansion of this resource, by also incorporating large‑scale 
datasets derived from other cancer tissue type studies, will 
allow us to not only investigate the biological relevance, 
importance and usefulness of individual biomolecules, but 
also to identify potential intervention points or markers of 
high prognostic/diagnostic value prior to evaluation and 
validation in patient cohorts. Potential applications of such 
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findings will most likely include the use of multiplexed plat-
forms, since it was shown that integrating various molecule 
types, such as proteins and miRs, can exert a beneficial 
effect on overall sensitivity and specificity of a bioassay for 
pancreatic cancer (64). However, this also emphasises that 
further study is required to use novel approaches and may 
lead to better outcomes in patient stratification and disease 
treatment.
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